Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (PLRX)
NASDAQ:PLRX
Pliant Therapeutics (PLRX) Stock Price & Analysis
357 Followers
PLRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.29 - $20.23
Previous Close$10.52
Volume295.88K
Average Volume (3M)505.12K
Market Cap
$634.63M
Enterprise Value$151.75M
Total Cash (Recent Filing)$494.25M
Total Debt (Recent Filing)$11.37M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 05, 2024EPS Estimate
-$0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.86
Shares Outstanding60,325,832
10 Day Avg. Volume589,308
30 Day Avg. Volume505,118
Standard Deviation0.27
R-Squared0.05
Alpha-0.00903
Financial Highlights & Ratios
Price to Book (P/B)1.40
Price to Sales (P/S)419.61
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue96.05
Enterprise Value/Gross Profit96.05
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$41.88Price Target Upside298.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Pliant Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive Phase IIa PET imaging trial results further support the efficacy of bexotegrast in IPF.
Efficacy And Mechanism Of ActionBexotegrast treatment led to improved enhanced liver fibrosis (ELF) scores and pro-peptide of type III collagen formation (PRO-C3) compared to placebo, supporting bexotegrast's antifibrotic mechanism of action.
Safety ProfileBexo's safety profile continues to appear clean with no study discontinuations or serious adverse events reported and most treatment emergent adverse events were mild in severity.
Bears Say
Clinical TrialsFailed or equivocal trial results pose significant downside risks to the rating and price target.
Financial PerformancePLRX reported a net loss driven by increased operational expenses, despite a decrease in stock-based compensation.
Regulatory ApprovalThe FDA has not yet accepted the adaptive trial design, creating uncertainty around regulatory approval.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PLRX FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $10.29 and its highest was $20.23 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Currently, no data Available
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 29 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on May 06, 2024. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.772 by -$0.008.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -$0.85.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 60,325,832 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.772. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Among the largest hedge funds holding Pliant Therapeutics’s share is RA Capital Management. It holds Pliant Therapeutics’s shares valued at 19M.
---
Pliant Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.88 (298.10% Upside)
$41.88 (298.10% Upside)
Blogger Sentiment
Bullish
PLRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 14.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.93%
12-Months-Change
Fundamentals
Return on Equity
-34.17%
Trailing 12-Months
Asset Growth
-12.76%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
---
PLRX Stock 12 Month Forecast
Average Price Target
$41.88
▲(298.10% Upside)
Technical Analysis
Best Analysts Covering PLRX
1 Year
1 Year Success Rate
6/19 ratings generated profit
1 Year Average Return
+37.03%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 31.58% of your transactions generating a profit, with an average return of +37.03% per trade.
---